VRTX monthly performance report
Monthly VRTX research: returns, drawdown, relative strength, seasonality, and key stats.
VRTX monthly report
—
Key takeaways
- Vertex Pharmaceuticals (VRTX) closed August 2026 at $484.83, up 1.62% for the month and +29.29% over the trailing 12 months.
- Year-to-date, VRTX is +6.94%, underperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading +6.77% versus its 200-day moving average ($454.09), a bullish technical signal.
- Over the past three years, VRTX has underperformed the S&P 500 by −29.89%, with a relative strength index reading of 82.2.
- Win rate over the trailing 39 months stands at 64.1% — 25 positive months versus 14 negative months.
Vertex Pharmaceuticals ended August 2026 at $484.83, posting a monthly return of +1.62%. The S&P 500 returned +3.05% over the same window, leaving relative performance at −1.43%.
The current quarter stands at −2.37% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +6.77% versus the 200-day moving average ($454.09).
Year-to-date, VRTX is +6.94% against SPY +12.89%, a gap of −5.94%. The stock is currently −8.84% below its 52-week high, with maximum 3-year drawdown at −29.07%.
| Period | VRTX | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +1.28% | −0.20% | +1.48% |
| 1 Week | −1.13% | +3.90% | −5.04% |
| 1 Month | +1.62% | +3.05% | −1.43% |
| 3 Months | +13.44% | +7.11% | +6.33% |
| 6 Months |